Steve Yang, Ph.D
A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco.
Qunsheng Ji, Ph.D
Vice President, Head of Oncology and Immunology Unit
Over 15 years of industry experience in drug discovery and translational science especially in oncology and recently renal diseases. Ph.D from Chinese Academy of Medical Science/ Peking Union Medical College, jointed with Vanderbilt University USA, Medical degree from First Military Medical University in Guangzhou.
Henry Lu, Ph.D
Vice President, Head of Discovery Biology Unit
Over 20 years’ experience in biological research and pharmaceutical industry. Formerly Adjunct Associate Professor at the University of California San Francisco, Senior Director of Infectious Diseases at Rigel Pharmaceuticals Inc. B.S. from Fudan University, Ph.D from the Shanghai Institute of Biochemistry, Academia Sinica.
Letian Kuai Ph.D.
Executive Director, Head of HitS
With 10+ years’ experience in DNA-encoded library (DEL) technology, Letian joined WuXi AppTec HitS in 2018 and is currently the head of HitS. After joining the HitS as R&D team leader, Letian continuously devotes to build the world-leading hit finding platform and develop unique screening strategy & analytic methodology.
Peiyuan Lin, PH.D
Senior Vice President, HD Biosciences
Peiyuan Lin joined HD Biosciences (Wuxi subsidiary company) as Senior VP in 2008, leading R&D efforts in drug discovery. Peiyuan Lin earned her Ph.D. in molecular pharmacology from the University of Cincinnati College of Medicine in 1988. Since then, she has gained extensive knowledge and experience working internationally over the last 30 years in both Pharmaceutical Drug Discovery and the CRO industry.
Declan Ryan, Ph.D
Vice President, US Business Development
Over 20 years' experience in R&D in both research and business development roles at 3-Dimensional Pharmaceuticals, Novartis, Johnson & Johnson, AMRI and Shanghai ChemPartner. Ph.D from University of Lausanne, Switzerland and Post-doc studies at Yale University and University of Pittsburgh, USA.
Dave Madge, Ph.D
Vice President, EU and Israel BD Head
Over 20 years’ experience working within academia, biotech and CROs. Former VP Research at Xention, founder of NCE Discovery (now Domainex) and a member of the integrated biomedical research group at University College London. Dave started his career at the Wellcome Foundation and received his Ph.D in Chemistry from Imperial College, London.